Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors

NCT04956640 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT04956640
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04956640 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors
Lead sponsor
Eli Lilly and Company
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
July 19, 2021
Completion date
April 30, 2027
Enrollment
540 (estimated)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract neoplasms, carcinoma, non-small-cell lung, colorectal neoplasms, endometrial neoplasms, ovarian neoplasms, pancreatic neoplasms